35000名患者系统分析发现，替尔泊肽在减重和多个代谢参数改善均位列三甲

Core Viewpoint - Tirzepatide is emerging as a leading candidate for treating overweight and obesity due to its significant weight loss effects and improvements in various metabolic parameters [5][7][8]. Group 1: Clinical Efficacy and Market Demand - In the SURMOUNT-5 clinical study, Tirzepatide demonstrated an average weight loss of 20.2% over 72 weeks in overweight adults with related comorbidities, significantly surpassing Semaglutide's 13.7% [8]. - Tirzepatide received approval for obesity treatment in November 2023 and for moderate to severe obstructive sleep apnea in December 2024, marking it as the first drug approved for this condition [8]. Group 2: Mechanism of Action - Tirzepatide activates GIP/GLP-1 receptors, promoting insulin secretion, inhibiting glucagon release, delaying gastric emptying, and suppressing appetite, which collectively aid in weight management and blood sugar control [9]. Group 3: Indications for Use - Tirzepatide is indicated for type 2 diabetes patients, particularly those with poor blood sugar control despite other treatments and those needing weight loss [10]. - It is also indicated for obesity management in adults with a BMI of ≥28 kg/m² or ≥24 kg/m² with at least one weight-related comorbidity [11]. Group 4: Contraindications and Cautions - Tirzepatide is not suitable for type 1 diabetes patients, those with acute diabetic ketoacidosis, severe gastrointestinal diseases, or a history of medullary thyroid carcinoma [12][13][14].